Patents by Inventor Daniel Dix

Daniel Dix has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
    Publication number: 20230374108
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Application
    Filed: June 29, 2023
    Publication date: November 23, 2023
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric FURFINE, Daniel DIX, Kenneth GRAHAM, Kelly FRYE
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 11732024
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Grant
    Filed: June 15, 2021
    Date of Patent: August 22, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
  • VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
    Publication number: 20210340220
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Application
    Filed: June 15, 2021
    Publication date: November 4, 2021
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric FURFINE, Daniel DIX, Kenneth GRAHAM, Kelly FRYE
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 11084865
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: August 10, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
  • Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
    Patent number: 11071780
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: July 27, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Robert L. Vitti, Kristine A. Erickson, Karen W. Chu, Stanley J. Wiegand, Jingtai Cao, Ivan B. Lobov, Saurabh Wadhwa, Kenneth S. Graham, Daniel Dix
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 11066458
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: July 20, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
  • Stabilized Formulations Containing Anti-NGF Antibodies
    Publication number: 20210107974
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human nerve growth factor (hNGF). The formulations may contain, in addition to an anti-hNGF antibody, at least one non-ionic surfactant, at least one sugar, and acetate. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: December 7, 2020
    Publication date: April 15, 2021
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Scott Walsh, Terra Potocky, Daniel Dix, Renuka Sivendran
  • VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
    Publication number: 20200131246
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Application
    Filed: January 10, 2020
    Publication date: April 30, 2020
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric FURFINE, Daniel DIX, Kenneth GRAHAM, Kelly FRYE
  • VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
    Publication number: 20200017572
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Application
    Filed: September 25, 2019
    Publication date: January 16, 2020
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric FURFINE, Daniel DIX, Kenneth GRAHAM, Kelly FRYE
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 10464992
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO: 4.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: November 5, 2019
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 10400025
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: September 3, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
  • PROCESS FOR REDUCING SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION
    Publication number: 20190231877
    Abstract: The present disclosure provides a stable protein composition containing a surfactant and having less than 400 subvisible particles of 10 microns or greater diameter per container, or less than 10,000 subvisible particles of 2 microns or greater per container. A method of manufacturing such a stable protein composition is disclosed, which includes a unit of operation that removes or decreases an esterase activity that degrades the surfactant. The unit of operation may be hydrophobic interaction chromatography or filtration, mixed mode chromatography, or the like.
    Type: Application
    Filed: April 8, 2019
    Publication date: August 1, 2019
    Inventors: Hanne BAK, John MATTILA, Ning LI, Xiaolin TANG, Daniel DIX, Chen LI, William MARKIS
  • Process for reducing subvisible particles in a pharmaceutical formulation
    Patent number: 10342876
    Abstract: The present disclosure provides a stable protein composition containing a surfactant and having less than 400 subvisible particles of 10 microns or greater diameter per container, or less than 10,000 subvisible particles of 2 microns or greater per container. A method of manufacturing such a stable protein composition is disclosed, which includes a unit of operation that removes or decreases an esterase activity that degrades the surfactant. The unit of operation may be hydrophobic interaction chromatography or filtration, mixed mode chromatography, or the like.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: July 9, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Hanne Bak, John Mattila, Ning Li, Xiaolin Tang, Daniel Dix, Chen Li, William Markis
  • METHODS AND FORMULATIONS FOR TREATING VASCULAR EYE DISEASES
    Publication number: 20190117767
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).
    Type: Application
    Filed: December 28, 2018
    Publication date: April 25, 2019
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Robert L. VITTI, Kristine A. ERICKSON, Karen W. CHU, Stanley J. WIEGAND, Jingtai CAO, Ivan B. LOBOV, Saurabh WADHWA, Kenneth S. GRAHAM, Daniel DIX
  • VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
    Publication number: 20190031735
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO: 4.
    Type: Application
    Filed: October 12, 2018
    Publication date: January 31, 2019
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric FURFINE, Daniel DIX, Kenneth GRAHAM, Kelly FRYE
  • STABILIZED FORMULATIONS CONTAINING ANTI-NGF ANTIBODIES
    Publication number: 20190010222
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human nerve growth factor (hNGF). The formulations may contain, in addition to an anti-hNGF antibody, at least one non-ionic surfactant, at least one sugar, and acetate. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Application
    Filed: September 19, 2018
    Publication date: January 10, 2019
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Scott Walsh, Terra Potocky, Daniel Dix, Renuka Sivendran
  • VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION
    Publication number: 20180155408
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Application
    Filed: January 24, 2018
    Publication date: June 7, 2018
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric FURFINE, Daniel DIX, Kenneth GRAHAM, Kelly FRYE
  • VEGF antagonist formulations suitable for intravitreal administration
    Patent number: 9914763
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: March 13, 2018
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric Furfine, Daniel Dix, Kenneth Graham, Kelly Frye
  • Stabilized formulations containing anti-DLL4 antibodies
    Patent number: 9675692
    Abstract: The present invention provides pharmaceutical formulations comprising an antibody that specifically binds to human delta-like ligand 4 (Dll4). The formulations may contain, in addition to an anti-Dll4 antibody, a phosphate buffer, an organic cosolvent, a disaccharide, and a salt. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months and after being subjected to thermal and other physical stress.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: June 13, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Scott Walsh, Daniel Dix
  • METHODS AND FORMULATIONS FOR TREATING VASCULAR EYE DISEASES
    Publication number: 20170080086
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an angiopoietin-2 (Ang-2) inhibitor such as an anti-Ang-2 antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (e.g., aflibercept).
    Type: Application
    Filed: December 6, 2016
    Publication date: March 23, 2017
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Robert L. VITTI, Kristine A. ERICKSON, Karen W. CHU, Stanley J. WIEGAND, Jingtai CAO, Ivan B. LOBOV, Saurabh WADHWA, Kenneth S. GRAHAM, Daniel DIX